Purchase Order 75N95020P00765
Award Date 9/29/20
Potential Completion Date 11/30/23
Potential Value $22K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Set-Aside Type
Total Small Business
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Trenton, NJ 08638, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $99,000 firm fixed price purchase order to Targetmol Chemicals Inc. to synthesize analogs of repsox and intermediates from two ongoing medicinal chemistry projects. Over a six-month period after receipt of order, Targetmol will synthesize the requested compounds and deliver milligram to gram quantities to NCATS along with electronic progress reports, analytical data including LCMS and 1H NMR, and...
- The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) awarded a $30,035 firm fixed price purchase order to Medchemexpress LLC of Princeton, New Jersey for the synthesis of synthetic compounds to support NCATS. Under the terms of the award, Medchemexpress will provide synthetic compound synthesis services to NCATS by November 11, 2022. No set-aside provisions were applied to this procurement. As the lead institute for NIH's translational...
- Medchemexpress LLC has been awarded a firm fixed price purchase order valued at $24,700 by the National Institutes of Health's National Center for Advancing Translational Sciences to provide 29 compounds in support of the agency's Tox21 research project examining the NS3-NS2B complex. As part of its mission to translate scientific discoveries into clinical applications, NCATS utilizes screening programs like Tox21 to evaluate the effects of environmental chemicals on biological pathways...
- This $16,035 firm-fixed price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the U.S. Department of Health and Human Services, to MedChemExpress LLC, a New Jersey-based foreign-owned minority-owned small business. The award is for the acquisition of 2 grams of Minnelide (CAS: 1254702-87-8) and 10 grams of GNE-618 (CAS: 1362151-42-5), which are chemical compounds used to support NCATS' biomedical research programs. MedChemExpress has...
- The National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a $240,000.00 firm fixed-price purchase order to Chemogenics Biopharma, LLC, a for-profit limited liability company, for custom synthesis and bioanalytical services to support NCATS' internal projects focused on developing small molecule inhibitors of physiological small molecule methyltransferases. The 12-month contract is not set aside and is awarded under FAR Part 13 simplified...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $103,000.00 firm-fixed-price purchase order to ChemDiv, Inc. to provide a compound library of 8,000 specific and unique small molecule compounds. The compounds are being procured for the National Center for Advancing Translational Sciences (NCATS) to support their Genesis screening library. The contract does not have a set-aside designation, and the place of performance is San...
- The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $143,245.20 firm-fixed-price purchase order to Biotage, LLC for a flash purification chromatography system with automated mass-directed fraction collection. The system will enable NCATS chemists to verify the identity of compounds during flash chromatography purification, eliminating the need for separate manual LCMS analysis. This contract does not...
- This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH), to Life Chemicals USA, Inc. for $50,697.50. The order is for a screening compound set of 3,750 small molecules to be used in the Genesis screening library. The purchase was made through a non-competitive combined synopsis/solicitation process. There was no set-aside designation for this award. The award has a...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Cyprotex US LLC, a foreign-owned for-profit organization, for $153,215.00 to conduct testing of compounds in absorption, distribution, metabolism, and excretion (ADME) assays over a 1-year period from March 5, 2021 to March 4, 2022. The contract was awarded sole-source without full and open...
- Organix Chemistry Solutions LLC was awarded a $3.677 million delivery order against the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences' CRO Support for NCATS Medicinal Chemistry for Lead Optimization master IDIQ contract. The delivery order, issued for the period of September 28, 2020 through September 27, 2022, provides synthetic chemistry support services to the TDB Medicinal Chemistry Team. Key services will involve...
COMPOUNDS SYNTHESIS FOR NCATS ETB PROBE PORTAL
Posted 9/29/20
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Compounds synthesis for NCATS ETB probe portal | 75N95020Q00320 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Solicitation 1/1 | 9/8/20, 6:02 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Funding Only Action | ($8k) | 3/20/23 | |
| Not listed | Not listed | $29.7k | 9/29/20 |